DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
当前地点:
>
> This Story


注册记数器 to rate this News Story
Forward Printable StoryPrint Comment

 

 

Molecular Imaging Homepage

BWXT to acquire Sotera Health’s Nordion medical isotope business $150M in capital expenditures expected this year

Canada forms council for radioisotope production Seeks to raise awareness about importance of medical isotope production to the public

Imaging innovation yields new insights into cardiac health As ultrasound analytics increase, other cardiac imaging tools become more accurate and affordable

NVIDIA aims to bring AI insights to existing global fleet of imaging systems With Project Clara, older scanners may gain remote access to latest capabilities

Researchers develop PET tracer that may predict effectiveness of depression treatment Could be used for other mental disorders

New PET imaging agent may help guide treatment for neurodegenerative diseases Preclinical study generates favorable results

MGH researchers develop AI technique for fast, high-quality imaging scans Image reconstruction in a fraction of a second

CereMetrix Silver neuroimaging analytics platform scores FDA approval Quantifies brain function down to the voxel level

New PET imaging agent predicts tumor response to lung cancer drug Could lead to better patient management and outcomes

PET beats SPECT for detecting coronary artery disease: study Detected 79 percent of severe obstructive cases versus 70 percent

Longitudinal PET imaging with 18F-AV45

PET tracer may help assess promising Alzheimer's treatment

Lauren Dubinsky , Senior Reporter
Belgian researchers uncovered that the 18F-AV45 PET imaging agent can determine the effectiveness of a new Alzheimer’s disease treatment.

Over five million Americans currently live with the disease, and in the next three decades that’s expected to swell to 16 million, according to the Alzheimer’s Association. To prevent that from happening, the industry is working toward developing a viable treatment option.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



"The aim of this translational research is advancing results discovered at the bench so that they can be applied to patients at the bedside," said Dr. Steven Staelens, lead author of the study.

The treatment under investigation for this study is the chronic administration of an inhibitor for the beta (β)-site amyloid precursor protein-cleaving enzyme 1 (BACE1). It cuts off protein fragments that can result in amyloid-β development by binding to BACE1.

In a mouse experiment, the researchers compared a control group with a group genetically-altered to have Alzheimer’s and tested the radiotracers 18F-AV45, 18F-FDG PET and 18F-PBR111. At the seven-week mark, the mice received the BACE inhibitor and then brain metabolism, neuroinflammation and amyloid-β pathology were measured with a micro-PET scanner and each of the tracers.

Baseline scans were then performed at six to seven weeks and follow-up scans were done at four, seven and 12 months. In particular, 18F-AV45 uptake was measured at eight and 13 months of age and microscopic studies were performed following the final scans.

"The study is unique, as BACE1 inhibition was administered by oral gavage individually in more than 110 mice daily soon after birth up to 15 months of age, while repetitive longitudinal scans were acquired every 3 months with three different tracers looking at ABeta plaque load, brain metabolism as well as neuroinflammation," said Staelens.

All of the tracers detected pathological differences between the mice with Alzheimer’s and the controls, but only 18F-AV45 revealed the effects of the inhibitor treatment. It identified reduced amyloid-β pathology in the mice with Alzheimer’s, and that was confirmed in the microscopic studies.

However, the researchers cautioned that it’s very important to accurately quantify amyloid-beta tracers and that the nonspecific uptake in the brain of subjects might be underestimated for some existing Alzheimer’s tracers that have quick metabolism profiles.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

做广告
提升您的品牌知名度
拍卖+私人销售
获得最好的价格
买设备/配件
找到最低价格
每日新闻
阅读最新信息
目录
浏览所有的DOTmed用户
DOTmed上的伦理
查看我们的伦理计划
金子分开供营商节目
接收PH要求
金子服务经销商节目
接收请求
提供保健服务者
查看所有的HCP(简称医疗保健提供商)的工具
工作/训练
查找/申请工作
Parts Hunter +EasyPay
获取配件报价
最近证明
查看最近通过认证的用户
最近额定
查看最近通过认证的用户
出租中央
租用设备优惠
卖设备/配件
得到最划算
服务技术员论坛
查找帮助和建议
简单的征求建议书
获取设备报价
真正商业展览
查找对设备的服务
对这个站点的通入和用途是受期限和条件我们支配 法律公告 & 保密性通知
物产和业主对 DOTmed.com,公司 Copyright ©2001-2018 DOTmed.com, Inc.
版权所有